TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05595473
Drug: RZ-001 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 4 and VGCV
Study: NCT05327530
Drug: NKTR-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study: NCT06104683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00850512
Drug: CHOP21-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four months for CHOP21-R and two treatment days one week apart
Study: NCT05372315
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: (dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
Study: NCT06398392
Drug: [18F]PBR111
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
Study: NCT05427630
Drug: THC ~2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower containing THC \~2.5%
Study: NCT05427630
Drug: THC ~5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower containing THC \~5%
Study: NCT05427630
Drug: THC ~10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower containing THC \~5%
Study: NCT05465681
Drug: HR20013 for injection；dexamethason
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study: NCT06178640
Drug: Simvastatin 40 mg film-coated tablet
Normalized name: simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg film-coated tablet
Study: NCT06178640
Drug: Zocor 40 mg film-coated tablet
Normalized name: simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
Study: NCT05045053
Drug: Xiidra 5% Ophthalmic Solution
Normalized name: Xiidra 5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
Study: NCT05459805
Drug: traditional chinese medicine Xuanfei-Zhike formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200ml, bid, for 8 weeks
Study: NCT06342167
Drug: Programmed Cell Death Protein 1 Inhibitor
Normalized name: Programmed cell death protein 1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
Study: NCT05127772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
Study: NCT01539265
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05578521
Drug: Cerebralcare pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: a dose of 2 packages, twice a day of Cerebralcare pills
Study: NCT05578521
Drug: Cerebralcare pills placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebralcare pills placebo will be administrated at the same rate with experimental group
Study: NCT06618313
Drug: JCXH-213,an mRNA-LNP based in vivo CAR therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCXH-213 infusion
Study: NCT06512402
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
Study: NCT06512402
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
Study: NCT04309721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Study: NCT05165394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT06111326
Drug: BC3402 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
Study: NCT05976737
Drug: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
Study: NCT05976737
Drug: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Study: NCT05509244
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1g iv dripping at end of surgery
Study: NCT05509244
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 300mg iv dripping at end of surgery
Study: NCT06289725
Drug: antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
Study: NCT05012566
Drug: Vistabex
Normalized name: ascorbic acid / biotin / calcium pantothenate / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine mononitrate Oral Tablet [Vitabee with C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
Study: NCT05533125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 250ml NaCl 0.9% intravenously with usual premedication
Study: NCT05817721
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
Study: NCT06037655
Drug: Total Neoadjuvant Treatment
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
Study: NCT04936880
Drug: Control: Analgesia-sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
Study: NCT05111249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral solution once weekly
Study: NCT05964738
Drug: Diuretics withdrawal
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
Study: NCT05964738
Drug: Diuretics maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any diuretic could be used
Study: NCT05635838
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT05955027
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: a drug to treat influenza, oral
Study: NCT05955027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control, oral
Study: NCT06530849
Drug: GC012F Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
Study: NCT05153408
Drug: BLU-701
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLU-701 for oral administration
Study: NCT04918589
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL topical of 0.9% normal saline
Study: NCT06052462
Drug: [14C]-LY3556050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04887311
Drug: MBM-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
Study: NCT06613217
Drug: zelenirstat
Normalized name: Zelenirstat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
Study: NCT02082691
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
Study: NCT06086912
Drug: HR17031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
Study: NCT06086912
Drug: HR17031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
Study: NCT06086912
Drug: HR17031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
Study: NCT05880914
Drug: Standard treatment for bone disorder
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
Study: NCT05689827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was used in the same way
Study: NCT05748600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo tablet
Study: NCT05966701
Drug: SSGJ-613
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSGJ-613 subcutaneous injection.
Study: NCT05966701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection.
Study: NCT05418361
Drug: ACE inhibitor ,angiotensin receptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients taking ACEI or ARBs with cardiovascular disease
Study: NCT04853797
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Study: NCT04853797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (calcium supplements).
Study: NCT05669885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive oral administration of placebo.
Study: NCT06202261
Drug: TQB2930 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2930 for injection is a HER2 bispecific antibody.
Study: NCT06202261
Drug: TQB3616 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Study: NCT06202261
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
Study: NCT05420012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Study: NCT05396118
Drug: Injection of hyperpolarized [1-13C]Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
Study: NCT05211050
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
Study: NCT04679389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally or enterally
Study: NCT06147037
Drug: FPI-2053
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPI-2053 is a bispecific antibody that targets EGFR and cMET
Study: NCT06147037
Drug: [111In]-FPI-2107
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053).
Study: NCT06147037
Drug: [225Ac]-FPI-2068
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period.
Study: NCT06085365
Drug: Immunonutrition （Su yusu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
Study: NCT06085365
Drug: fluorouracil based chemotherapy regimens
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil based chemotherapy regimens
Study: NCT06411379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06671496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zasocitinib matching placebo.
Study: NCT05148494
Drug: Fleet Enema
Normalized name: Fleet Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard pre-op application, see arm description
Study: NCT04776369
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV 50 ml
Study: NCT05652660
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Probe substrate
Study: NCT05008510
Drug: Sabizabulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabizabulin (Veru-111)
Study: NCT05295329
Drug: Compound Danshen Dropping Pills
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: use Compound Danshen Dropping Pills
Study: NCT06434740
Drug: Puterizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
Study: NCT05491642
Drug: BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05491642
Drug: Placebo to BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05781399
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching film-coated placebo tablet
Study: NCT05485012
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind administration of an opioid agonist
Study: NCT05113004
Drug: Mycophenolate mofetil 2000mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Study: NCT05113004
Drug: Placebo of Mycophenolate mofetil 2000mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Study: NCT06017284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 100 mg/day, once a day, orally intake at night.
Study: NCT05926258
Drug: Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops
Normalized name: Oxybuprocaine hydrochloride 4 mg/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: ocular surface anesthesia
Study: NCT04804553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the matching placebo orally.
Study: NCT04824872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for dasiglucagon
Study: NCT04634162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study: NCT05176210
Drug: PS1
Normalized name: ACL11SPS12 NERVE BLOCK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Study: NCT05176210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as a 120 mg tablet.
Study: NCT05677945
Drug: 3Mixtatin paste: Simvastatin mixed with modified triple antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.
Study: NCT05677945
Drug: 3Mix: Modified triple antibiotic mix in propylene glycol
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.
Study: NCT05282706
Drug: Mandarin Oil
Normalized name: mandarin oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: A hydrogel mandarin oil infused aromatherapy patch
Study: NCT05193994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT06489626
Drug: Methylprednisolone 4 milligram Tab
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-day 4 milligram methylprednisolone oral taper
Study: NCT05546788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received placebo gel
Study: NCT04267237
Drug: RO7198457
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
Study: NCT04872985
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, q3w\*4
Study: NCT04872985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg orally once per day
Study: NCT05872425
Drug: DingKunDan(GuangYuYuan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment.
Study: NCT05872425
Drug: Drospirenone and Ethinylestradiol Tablets (Ⅱ)
Normalized name: drospirenone and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
Study: NCT05429515
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy protocol will be made by hematologists.